EUCTR2005-005910-20-HU进行中（未招募）不适用
A 12-Week Efficacy and Safety Study of Two Doses of Mometasone Furoate/Formoterol Combination Formulation Compared With Mometasone Furoate Monotherapy, in Persistent Asthmatics Previously treated With High-Dose Inhaled Glucocorticosteroids
Schering-Plough Research Institute, a division of Schering Corporation0 个研究点目标入组 621 人开始时间: 2006年8月7日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 621
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •A subject must have been using high dose Inhaled Corticosteroid (ICS) (either alone or in combination with a Long Acting beta-Agonist (LABA)) for at least 12 weeks prior to Screening and have no use of oral corticosteroids within 30 days prior to Screening. A subject must have been on a stable asthma regimen (daily dose unchanged) for at least two weeks prior to Screening. High dose ICS is defined in the protocol.
- •A subject must have experienced at least one severe exacerbation requiring a course of oral glucocorticosteroids 2 – 12 months prior to Screening.
- •If, in the medical judgement of the Investigator, there is no inherent harm in changing a subject’s current asthma therapy, a subject must be willing to discontinue their prescribed ICS or ICS/LABA combination at the Screening Visit, and be transferred to open-label treatment with MF MDI 400 microgram BID for 2-3 weeks prior to the Baseline/Randomization Visit.
- •To document the diagnosis of asthma and assure the subject's responsiveness to bronchodilators before randomization, one of the following methods can be used at the Screening Visit, Day -14, or thereafter, but prior to the Baseline Visit:
- •* The subject must demonstrate an increase in absolute FEV1 of at least 12% and at least 200 mL within 15 minutes after administration of four inhalations of albuterol/salbutamol (total dose of 360 to 400 micrograms).
- •* The subject must demonstrate a PEF variability of more that 20% expressed as a percentage of the best and lowest morning pre-bronchodilator PEF over at least one week.
- •* The subject must demonstrate a diurnal variation in PEF of more than 20% based on the difference between the pre-bronchodilator morning value and the post-bronchodilator value from the evening before, expressed as percentage of the mean daily PEF value.
- •At the Screening Visit, the subject's FEV1 must be >=50% predicted when all restricted medications have been withheld for the appropriate intervals.
- •Clinical laboratory tests conducted at the Screening Visit must be within norrmal limits or clinically acceptable to the investigator/sponsor. An ECG performed at the Screening Visit using a centralized transtelephonic technology must be clinically acceptable to the investigator. A chest X-ray performed at Screening Visit or within 12 months prior to the Screening Visit must be clinically acceptable to the investigator.
- •A subject must meet other specified spirometry and clinical laboratory test criteria, and female subjects of childbearing age must be using medically acceptable and adequate forms of birth control.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •A subject who demonstrates a change (increase or decrease) in absolute FEV1 of > 20% at any time from the Screening Visit up to and including the Baseline Visit.
- •A subject who requires the use of >8 inhalations per day of Short Acting beta-Agonist (SABA) MDI or >2 nebulized treatments per day of 2.5 mg SABA, on any 2 consecutive days from the Screening Visit up to and including the Baseline Visit.
- •A subject who experiences a decrease in AM or PM PEF below the Screening Period stability limit (as specified in the protocol) on any 2 consecutive days prior to randomization.
- •A subject who experiences an occurence of any clinical deterioration of asthma that results in emergency treatment, hospitalization due to asthma, or treatment with additional, excluded asthma medication (other than SABA) as judged by the clinical investigator at any time from the Screening Visit up to and including the baseline Visit.
- •A subject who is a smoker or ex-smoker and has smoked within the previous year or has had a cumulative smoking history of > 10 pack-years.
研究者
相似试验
进行中（未招募）
不适用
A 12-Week Efficacy and Safety Study of Two Doses of Mometasone Furoate/Formoterol Combination Formulation Compared With Mometasone Furoate Monotherapy, in Persistent Asthmatics Previously treated With High-Dose Inhaled GlucocorticosteroidsAsthmaMedDRA version: 8.1Level: LLTClassification code 10003553Term: AsthmaEUCTR2005-005910-20-DKSchering-Plough Research Institute, a division of Schering Corporation621
已完成
不适用
Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04431AM2)(COMPLETED)-J45J45PER-094-06SCHERING PLOUGH DEL PERU S.A.,
已完成
不适用
Evaluation of Two Doses of QVAR by Breath Operated and Metered Dose Inhalers in Asthmatic ChildrePER-048-05IVAX RESEARCH, INC.,
已完成
4 期
A study to evaluate the effect of two doses of oral melatonin on anxiety and pain relief in patients undergoing lower limb surgeries.CTRI/2020/02/023330Department of Anaesthesiology and Critical care63
尚未招募
不适用
The clinical study of the efficacy of two doses of influenza vaccination to the patients with malignancies.Any kind of malignanciesJPRN-UMIN000011918Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Graduate School of Medicine, Kobe, Japan100